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Isolated and identiﬁed more than 30 years ago, humanT cell leukemia virus type 1 (HTLV-1)
is the etiological agent of adult T cell leukemia/lymphoma, an aggressive lymphoprolif-
erative disease of activated CD4+ T cells, and other inﬂammatory disorders such as
HTLV-1-associatedmyelopathy/tropical spastic paraparesis. A variety of animal models have
contributed to the fundamental knowledge of HTLV-1 transmission, pathogenesis, and to
the design of novel therapies to treat HTLV-1-associated diseases. Small animal models
(rabbits, rats, and mice) as well as large animal models (monkeys) have been utilized to sig-
niﬁcantly advance characterization of the viral proteins and of virus-infected cells in the early
steps of infection, as well as in the development of leukemogenic and immunopathogenic
processes. Over the past two decades, the creation of new immunocompromised mouse
strains that are robustly reconstituted with a functional human immune system (HIS) after
being transplanted with human tissues or progenitor cells has revolutionized the in vivo
investigation of viral infection and pathogenesis. Recent observations obtained in HTLV-1-
infected humanized HIS mice that develop lymphomas provide the opportunity to study
the evolution of the proviral clonality in humanT cells present in different lymphoid organs.
Current progress in the improvement of those humanized models will favor the testing of
drugs and the development of targeted therapies against HTLV-1-associated diseases.
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INTRODUCTION
Since antiquity, animals have been part of the human scientiﬁc
and biomedical landscape. Observational studies of animals as
well as experimental investigations using animals have greatly con-
tributed to the advancement of scientiﬁc knowledge. Thus, during
the last two centuries, biomedical research has largely progressed
through observations and experiments performed with a variety
of animals, some of which having obtained the status of animal
models in biomedical research during the last ﬁve decades. Data
obtained from in vivo biological systems using live animals have
progressively completed results from in vitro experimental studies.
While the great majority of animals are used in the ﬁeld of phar-
maceutical research and toxicology testing, they are also crucial
in the understanding of basic and important pathophysiologi-
cal processes. In particular, mechanisms sustaining the stepwise
progression of viral pathogenesis from virus entry to the devel-
opment of disease has greatly beneﬁted from the use of animal
models.
Human T cell leukemia virus type 1 (HTLV-1), the ﬁrst
retrovirus linked to a cancer in humans, was isolated from
fresh peripheral blood lymphocytes from patients with cuta-
neous T cell lymphoma more than 30 years ago. Approximately
20 million people are infected worldwide primarily in endemic
regions in Southern Japan, the Caribbean, Western Africa, and
Central and South America. Most infected individuals remain
asymptomatic for life, but approximately 5% develop adult
T cell leukemia/lymphoma (ATL) after decades of protracted viral
latency, whereas 1–3% develops inﬂammatory diseases, such as
the neurologic disorder known as HTLV-1-associated myelopa-
thy/tropical spastic paraparesis (HAM/TSP). Clinical features of
ATL include monoclonal expansion of leukemic CD4+CD25+ T
cells (with atypicalmulti-lobulatednuclei) in the peripheral blood.
This lymphoproliferative disease in its most aggressive form fol-
lows an acute and frequently fatal course with a median 1-year of
survival from the timeof diagnosis. Patients eventually succumb to
clinical complications, in part due to immunodeﬁciency-induced
opportunistic infections.
Human T cell leukemia virus type 1 is a single-stranded
diploid RNA virus that carries genetic information for structural
proteins and enzymes (e.g., Gag) and via alternatively spliced
mRNAs encodes proteins from open reading frames (ORFs) I–IV
(Figure 1).
Initial studies on the pathogenesis of ATL have mainly focused
on the role of the regulatory Tax (p40) protein, encoded by the
ORF IV in the pX proviral region and that behaves as a potent
viral and cellular transactivator. Tax promotes proviral transcrip-
tion and is critically involved in the proliferation of infected T
cells, by favoring cell-cycle progression and cell survival and by
promoting the activity of cellular transcription factors includ-
ing NF-κB, AP-1, SRF, and CREB. Interestingly, Tax provokes
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FIGURE 1 | HumanT cell leukemia virus type 1 genome with viral transcripts and encoded proteins.
genomic instability and suppresses host damage response, indi-
cating that Tax harbors oncogenic properties. However, clonal
proliferation of ATL cells is frequently associated with a Tax-low
or Tax-negative phenotype, as the result of genetic or epigenetic
events such as deletion of the 5′ LTR or methylation of this
region. Consequently, it is currently accepted that Tax is criti-
cally involved in ATL induction and appears to be dispensable
in the late stages of this disease. Such an assumption raises the
possibility that ATL development and maintenance are depen-
dent on the intervention of another viral product. A few years
ago, another regulatory protein named HBZ (HTLV-1 bZip fac-
tor) encoded by an ORF in the antisense strand of the HTLV-1
provirus was identiﬁed (Mesnard et al., 2006; Duc Dodon et al.,
2010). Since this novel viral product has been the subject of
intensive research efforts to determine its function in viral repli-
cation and/or pathophysiology. Thus, HBZ has been shown to
inhibit HTLV-1 transcription by interacting with and displacing
CREB from binding to the 5′ LTR and to intervene in the regu-
lation of infected T cells, thus maintaining the leukemic state of
these cells.
Other viral products such as the regulatory p27 Rex protein,
a product of the ORF III in pX region and the accessory p30
protein (product of ORF II) acting at the transcriptional and post-
transcriptional levels have been demonstrated to play a crucial role
in the initial stages of infection, mainly by modulating the level of
produced viral particles, allowing in turn the promotion of viral
persistence and evasion of the host immune surveillance. Likewise,
in vitro studies have underlined that another auxiliary p12 protein
(product of ORF I) that is also promoting viral persistence and
immune evasion, has the ability of promote T cell proliferation.
Finally the p13 protein (product of ORF II) was found to interact
with Tax and suppress its transactivation function and to control
the turnover of HTLV-1-infected T cells. In addition, p13, a mito-
chondria localized protein, inﬂuences cell survival (see for review,
Lairmore et al., 2011).
It is therefore not surprising that soon after the isolation and
characterization of HTLV-1 in 1980, animals were used with the
main purpose to uncover the natural history of HTLV-1 infection
and of associated diseases in humans. Thus, the use of both small
animals (e.g., rats and rabbits) and large animals (e.g., monkeys)
has contributed to an understanding of transmission, dissemi-
nation, and persistence of HTLV-1 infections. Likewise, induced
animal models created by genetic manipulations have been used to
delineate the involvement of speciﬁc viral genes on the initiation
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and development of pathophysiological processes in the initiation
and the development of HTLV-1-induced pathogenic processes.
Furthermore, immunodeﬁcient mice arisen through sponta-
neous mutations have paved the way not only to the xenograft
of leukemic cells, but also to the development of humanized
mouse models that have allowed new approaches in translational
research.
ANIMAL MODELS TO STUDY THE EARLY
STEPS OF INFECTION
A variety of animal models have been evaluated to study the early
events of HTLV-1 transmission and immunologic response to the
viral infection. Many of these models have provided important
information about viral and host determinants of infection. Rab-
bits, some non-human primates, and rats have been used to study
HTLV-1 transmission and spread, evaluate immune responses
against the infection and to test the efﬁcacy of vaccines (Arnold
et al., 2006). Rabbits can be consistently infected, but generally
do not develop disease, but simulate asymptomatic infections in
humans. Cynomolgus macaques (Macaca fascicularis) and squir-
rel monkeys (Saimiri sciureus) can be experimentally infected with
HTLV-1 and provide useful primate models of HTLV-1 infection
(Nakamura et al., 1986; Kazanji, 2000). The monkeys seroconvert,
but typically do not demonstrate any clinical signs of disease. Rats
have been useful to test immune responses to vaccines and can be
experimentally infected with HTLV-1. Because rats exhibit con-
siderable variation in the response to the infection depending on
the rat strain used, they are not reliable models to test the early
spread of the virus (Kannagi et al., 2000; Hakata et al., 2001).
Rabbits have been used extensively as a model of HTLV-1 infec-
tion due to the consistency of transmission, ease of handling, and
low cost of maintenance (Figure 2).
The rabbit model of HTLV-1 is a reproducible system to pro-
ducepersistent infectionswithwidespreaddistributionof the virus
similar to humans. The main disadvantage of this model is the
lack of spontaneous development of disease. As a model of infec-
tion the rabbit has played an indispensable role in evaluation of
immune responses, parameters of infection, routes of transmis-
sion, and viral genetic determinants of infection with the use of
HTLV-1 molecular clones. When compared to the non-human
primate model of infection, the rabbit is just as easily infected and
offers the advantage of being available in speciﬁc pathogen free
(SPF) strains. The ﬁrst studies in the 1980s, showed the ability
to infect rabbits using the intravenous route and the MT-2 cell
line (a T cell leukemia line derived from an ATL patient; Miyoshi
et al., 1985). Early studies with rabbits veriﬁed suspected routes
of transmission and indicated how antibody responses devel-
oped following exposure. These studies also provided important
knowledge about the early sequential events following inocula-
tion, and methods to detect proviral DNA in infected tissues.
The examination of antibody responses has shown that rabbits
respond similarly to humans infected with HTLV-1 and pro-
vided opportunities to test immunodominant viral epitopes for
use in vaccine approaches using synthetic peptides and recom-
binant vaccinia vectors. Immunization of rabbits with synthetic
peptides veriﬁed immunodominant epitopes of the viral envelope
protein (Env).
The development of infectious molecular clones in the 1990s
provided a unique tool for the evaluation of viral determinants
of HTLV-1. One of these clones, ACH, has been widely used to
develop stably transformed human and rabbit HTLV-1 positive T
cell lines for the use in in vivo studies (Collins et al., 1996). Sub-
sequently, ACH clones with mutations within the ORFs encoding
the HTLV-1 accessory proteins, p12, p13, and p30, were generated,
and used in rabbits to demonstrate the necessity of these accessory
proteins for establishment of infection and maintenance of provi-
ral loads. The rabbit model is useful to study the sequential events
during early HTLV-1 spread and offers a model to test therapeutic
strategies during mucosal transmission. An extensive study on the
early spatial and temporal events following intravenous inocula-
tion of HTLV-1 in New Zealand White rabbits indicated proviral
reservoirs in lymphoid organs and gut-associated lymphoid tissue
(GALT), particularly within intraepithelial lymphocytes (Haynes
et al., 2010). This information suggests that the GALT may be
a reservoir for infected lymphocytes prior to the development
of persistent infections. These data are consistent with a variety
of human studies that support emerging evidence that HTLV-1
promotes lymphocyte proliferation preceding early viral spread
in lymphoid compartments to establish and maintain persistent
infection. Immunosuppressive treatment prior to HTLV-1 infec-
tion in the rabbit model (similar to human transplant patients
exposed to contaminated blood products) results in enhanced
early viral expression.
Infectious clones were also critical to demonstrate the role of
pX ORF I and II in the early spread of the virus. Initial in vitro
studies with molecular clones with pX mutations suggested that
pX encoded proteins were not required for infectivity. However,
subsequent studies in the rabbit model showed that the proteins
encoded in pX ORF I and II were necessary for early establish-
ment of infection and maintenance of proviral loads (reviewed in
Lairmore et al., 2011). The ﬁrst evidence that pXORF Iwas impor-
tant for viral transmission was demonstrated in the rabbit model
using splice acceptor site mutant of the ACH infectious molecu-
lar clone. The deletion of this p12 acceptor splice site would also
introduce a frame shift in the HBZ antisense ORF, resulting in the
deletion of the last 24 amino acids of HBZ. However, the repli-
cation capacity of subsequent speciﬁc HBZ mutants in context of
molecular clones did not result in complete reduction of infectiv-
ity as observed in ORF I splice mutants. Thus, the rabbit model
was able to detect selected HBZ mutations and demonstrated that
these were different in viral spread compared to ORF I mutants
(Lairmore et al., 2011).
A recent study tested a variety of HTLV-1 mutant molecular
clones for their ability to replicate in dendritic cells (DCs) and
in vivo in rabbits and macaques (Valeri et al., 2010). In this study,
rabbits inoculated intravenously with these mutant clones had
reduced viral loads at 16 weeks post-inoculation before recovering
to “wild type” controls. DC cultures from macaques infected with
these mutant clones had reduced viral replication parameters sug-
gesting the importance of this cell type in early viral transmission
(Valeri et al., 2010). This study in macaques conﬁrmed the role of
proteins encoded in pX ORF I and II in viral transmission.
Collectively, using these animal models we now know that the
non-structural genes encoded from ORF I and II are vital for viral
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FIGURE 2 | Example of rabbit model of HTLV-1 transmission. Inoculation
of HTLV-1 transformed cells, e.g., R49 cells or Jurkat cell controls
intravenously or orally to establish infection. Viral parameters measured are
similar to those used to detect the infection in humans. PBMC, peripheral
blood mononuclear cells; MLN, mesenteric lymph nodes; GALT,
gut-associated lymphoid tissues.
infectivity, maintenance of the virus life cycle and proviral loads
in vivo, as well as host cell activation and regulation of viral gene
transcription. Limitations of the rabbit model include the lack of
consistent disease that mimic those observed in humans infected
with HTLV-1 and the lack of a wide-range of immunologic
reagents to assess the model.
TRANSGENIC AND XENOGRAFT MOUSE MODELS
Mouse models have the distinct advantage of being econom-
ical and readily available to test the growth of tumors. They
permit studies to test the development of tumors and to test
preclinical efﬁcacy of potential therapeutic agents. Multi-centric
growth of tumor cells transplanted into immunocompetent mice
is concurrent with elevated biomarkers such as PTHrP expres-
sion and increasing levels of serum interleukin (IL)-2Rα and β-2
microglobulin that correspond to increasing tumor burden. Even
if immunocompetent mice are not efﬁciently infected with HTLV-
1, they have been extensively used to produce animal models
exhibiting speciﬁc symptoms and pathology of diseases through
selective breeding and geneticmodiﬁcation. Thus, transgenicmice
have been very useful to test the role of HTLV-1 gene products in
the outgrowth of tumors (reviewed in Zimmerman et al., 2010).
Furthermore, the use of naturally immunodeﬁcientmice to harbor
cancer cells were crucial to the development of mouse xenograft
models have been developed to test organ engraftments with ATL
cell lines and tumor cells directly derived from ATL patients.
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TRANSGENIC MOUSE MODELS OF HTLV-1
Since the late 1980s, a variety of transgenicmousemodelswere cre-
ated to test the role of HTLV-1 gene products in tumor formation
or associated disease syndromes. Early models were primar-
ily focused on the Tax oncoprotein. Transgenic mouse models
demonstrated the role of Tax in cellular transformation and
deﬁned a variety of inﬂuences of Tax in cellular signaling pathways
such as NF-κB and serum response factor pathways (Nerenberg,
1990). Transgenic mice expressing the HTLV-1 tax gene under the
control of the LTR promoter developed multicentric mesenchy-
mal tumors of bone, nose, ear, mouth, tail, and foot (Ruddle et al.,
1993). This model clearly demonstrated the ability of Tax to elicit
tumor formation, despite the fact the model failed to produce
lymphomas or leukemia similar to ATL patients. Some of these
early transgenic mouse models also developed a wasting disease
characterized by degeneration of oxidative muscle ﬁbers, offer-
ing insights into the potential role of Tax in HTLV-1-associated
myopathies. LTR-tax mice also exhibited skeletal abnormalities
and salivary and lacrimal lesions similar to humans suffering from
Sjögren syndrome (Green et al., 1989).
By controlling Tax expression using the Lck promoter, lym-
phoma and leukemia have been produced in transgenic mice
(C57BL/6-Tg(Lck-HTLV-1 Tax) (Hasegawa et al., 2006). In this
model pre-T cell tumors were associated with constitutive NF-κB
activation. Similarly, by limiting expression of Tax to leuko-
cytes transgenic mouse (C57BL/6TgN(huGMZBTax) under the
control of the granzyme B promoter exhibit a large granular
lymphocytic leukemia and neutrophilic dominated inﬂamma-
tory lesions (Grossman et al., 1995). This mouse model has
recapitulated splenomegaly, lymphadenopathy, and inﬂamma-
tory masses on appendages. Interestingly, these transgenic mice
have humoral hypercalcemia of malignancy (HHM) and oste-
olytic bone lesions. This model has been extended by testing
Tax-mediated activationof luciferase inLTR-luciferase (LTR-LUC)
mice (C57BL/6TgN(LtrLuc) for imaging tumor engraftment
(Rauch et al., 2009).
Speciﬁcally, targeting Tax expression using bitransgenic and
doxycycline-inducible mice (Tg(EmuSR-tTa)83Bop) resulted in
activation of NF-κB and a fatal dermatologic disease character-
ized by inﬁltration of Tax positive T cells into the dermis and
epidermis (Kwon et al., 2005). Finally, a number of transgenic
C57/CBA mouse strains with tax under the regulatory control of
CD-3ε promoter enhancer sequence have developed mesenchy-
mal tumors at wound sites and mammary and salivary adenomas
(Hall et al., 1998).
Collectively, transgenic mice have provided reproducible mod-
els to test speciﬁc gene products role in tumor formation and
in targeting models have provided insights into the pathogenesis
of leukemia and paraneoplastic lesions associated with HTLV-1
gene products. A primary disadvantage of these models is the lack
of viral gene expression in context to an intact proviral genome
and lesion development that clearly mimics the pathogenesis of
HTLV-1-associated disease of humans.
XENOGRAFT MOUSE MODELS OF ATL
The possibility for human cells and tissues to be successfully trans-
planted into mice requires that these mice are compromised in
their capacity to reject xenogenic grafts as a consequence of an
absence of murine immune response. In 1966, the ﬁrst immuno-
compromised mice to be described were the athymic (nude) mice
(Flanagan, 1966). Later on formation of both murine mature T
and B lymphocytes was shown to be prevented in SCID mice
(CB17-Prkdcscid) bearing the severe combined immunodeﬁciency
the Prkdc (protein kinase, DNA activated, catalytic polypeptide)
mutation (Bosma et al., 1983). Engraftment of ATL cells and cell
lines within these mice is variable depending on which cell line is
evaluated. In general studies that use ATL cells obtained from
patients and have not been serially passaged are more reliable
in tumor outgrowth in this model. Studies in the SCID mice
indicated that irradiation or administration of antibodies to abro-
gate natural killer (NK) cell function was required for successful
engraftment of non-leukemic cells lines such as SLB-1 cells (Stew-
art et al., 1996). These observations have led to a reﬁnement of
mouse models with selected genetic defects in innate immune
function to further explore the role of speciﬁc effector cells in
tumor engraftment.
SCID/beige mouse (CB17.B6-Prkdcscid/Lystbg ) have defective B
and T cell function, NK cell activity, and defective granulocyte
properties. These mice have a higher rate of engraftment role of
multiple arms of the immune system in tumor engraftment and
spread. This tenet was further demonstrated in non-obese dia-
betic (NOD) mice that lack functional B and T cells, have low
NK cell activity, absence of complement activity, and impaired
macrophage and antigen presenting cell function. Compared to
the SCID mice and the SCID/bg mice, the NOD/SCID mice
(NOD.CB17-Prkdcscid/NCrCrl) are more susceptible to engraft-
ment with the HTLV-1 transformed cell lines (Parrula et al.,
2009). Inoculation of MET-1 cells into NOD/SCID mice results
in T cell leukemia with multiple organ involvement, which is
accompanied by increased serum calcium levels and enhanced
expression of receptor activator of nuclear factor κB ligand
(RANKL) on leukemic cells, and secretion of PTHrP and IL-6
(Zhang et al., 2003).
The development of the NOD/SCID mice containing a targeted
mutation in the beta-2 microglobulin gene (beta 2-m) resulted
in mice that lacked NK cell function (Kollet et al., 2000). This
strain of mouse offers the advantage of an increase percentage
of tumor engraftment and a reduced time to clinical signs com-
pared to NOD/SCID mice. NOD/SCID gamma c null (NOG;
NOD/Shi-scid/IL-2Rγnull) mice are homozygous for the SCID
mutation and a targeted disruption of the IL-2Rγ gene mutation.
One signiﬁcant advantage of NOG mice are efﬁciency to accept
transplanted with human cells compare to other mouse models.
These mice, in addition to lacking functional B, T, and NK cells,
have a severe reduction in interferon γ (IFN-γ) production which
allows these mice to be easily transplanted with ATL cells directly
from patients to test factors correlative to known paraneoplas-
tic syndromes associated with HTLV-1 infection, such as HHM
(Parrula et al., 2009).
THE USE OF HUMANIZED MICE TO RECAPITULATE
HTLV-1 INFECTION
Although xenograft animal models displaying multiple organ
engraftments with ATL cell lines or patient samples have been
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extensively studied, they failed to provide a complete understand-
ing of HTLV-1-associated ATL development. Thus, developing a
faithful animal model able to recapitulate the HTLV-1 infection,
and to understand the mechanisms of early infection up to the
development of associated pathologies is one of the critical goal in
HTLV-1 research.
Despite their advantages (small, easy-to handle and low-
cost, genetics easily manipulated), mice are not susceptible to
several human-speciﬁc pathogens, thus restricting their use in
experimental and medical research. This limitation has been over-
come with the development of humanized mice susceptible to
infection by these pathogens. Here, the “humanized mice” are
exclusively restricted to severely immunodeﬁcient mice that have
been engrafted with functional human cells and tissues. In those
animals, the engrafted human cells and tissues carry the same bio-
logical functions as they do in the human body. Consequently,
the physiological properties and functions of transplanted human
tissues and cells can be readily analyzed in the mouse.
Interestingly, during the last decades, constant efforts to
generate mouse models allowing an in vivo approach of the
human immune system (HIS) have been achieved by successful
genetic modiﬁcations of immunodeﬁcient mice and by improving
engraftment procedures. Actually, humanized mouse technology
has made rapid progress, and it is now possible to achieve high
levels of human chimerism in various organs and tissues, particu-
larly the immune system and the liver (Legrand et al., 2006a, 2009;
Shultz et al., 2007; Koyanagi et al., 2008; Manz and Di Santo, 2009;
Brehm et al., 2010; Cachat et al., 2012).
TOWARD THE GENERATION OF MICE WITH A FUNCTIONAL
HUMAN IMMUNE SYSTEM
Severe immunodeﬁciency in mice favors the engraftment
of a human immune system
The history of humanized mice truly began in 1983 with the
pioneering works of McCune and Mosier, who have transferred
in SCID mice (CB17-Prkdcscid) mature human peripheral blood
leukocytes (PBL) (hu-PBL-SCID) or transplanted human blood-
forming fetal liver cells, fetal bone, fetal thymus (thy), and human
fetal liver (liv) in SCID mice (SCID-hu or SCID-hu-thy/liv mice
(McCune et al., 1988; Mosier et al., 1988). Even if some level of
hematopoietic development has been achieved, these ﬁrst attempts
did not result in the de novo formation of a functional human
adaptive immune system. Indeed, the majority of human cells
engrafted were T cells, with few B cells, myeloid cells, and NK cells.
Furthermore, these humanized mice are “leaky,” spontaneously
generating murine T and B cells as they age and have high levels
of NK activity, both of which prevent efﬁcient/prolonged xeno-
engraftment. To note that HIV-1 infection of such humanized
mice has yielded valuable data ranging from the ﬁelds of in vivo
pathogenesis to drug efﬁcacy and passive immunity. However, in
these humanized mice, HIV-1 infections were often short-term,
providing data only on acute infection and no primary adap-
tive immune response was mounted against HIV-1. Nevertheless,
these hemato-lymphoid hu-PBL-SCID and -SCID mouse mod-
els have opened the way to extensive studies of the development
and function of the human immune and hematopoietic systems
and to the generation of mice with a decreased leakiness and with
a diminished level of NK cells. Improvements in the available
immunodeﬁcient mouse strains were reached with the NOD SCID
mice, commonly used because the NOD mutation results in a
reduction of NK cell activity (Suwanai et al., 2010). However, a
major disadvantage of the NOD strain is a signiﬁcant incidence
of spontaneous thymic lymphomas, which results in a shortened
lifespan.
A valuable mouse model called “BLT (for bone marrow, liver,
thymus) model” has been described in 2006 as a humanized
mouse model able to mount speciﬁc adaptive and innate immune
responses. These mice were obtained after transplantation of
autologous human hematopoietic fetal liver CD34+ cells into
NOD/SCID mice previously implanted with human fetal thymic
and liver tissues (Melkus et al., 2006;Wege et al., 2008). These mice
show long-term systemic repopulation with human T and B cells,
monocytes, macrophages, and DCs. T cells in these mice generate
human MHC class I- and II-restricted adaptive immune responses
to Epstein–Barr virus (EBV) infection and are activated by human
DCs to mount a potent T cell immune response to superantigens.
Another mouse model was obtained with mice deﬁcient in the
recombinase activating genes 1 and 2 (RAG1−/− and RAG2−/−,
respectively). They do not exhibit leaky production of murine
lymphocytes. However, RAG-deﬁcient animals produce normal
levels of NK cells, and thus additional mutations are required
in order to produce animals better suited for xeno-engraftment
studies.
The mutation in the common gamma chain receptor
A major technological breakthrough occurred with the creation of
RAG1−/−, RAG2−/−, and NOD–SCID mice that have mutations
in the common gamma chain receptor (γc, also referred to as the
IL-2 receptor gamma chain) gene. The γc is a component of the
IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors and is the gene
involved in X-linked SCID (Sugamura et al., 1996). Consequently,
lack of IL-7 signaling further blocks T and B cell development
while lack of IL-15 signaling also prevents maturation and expan-
sion of NK cells (Tassara et al., 1995; Ohbo et al., 1996). Since
SCID animals are experiencing leaky production of T and B cells,
the γc mutation is an useful means to further block maturation of
these cells. Finally, the inoculation of human CD34+ hematopoi-
etic progenitor and stem cells (HP/HSC) either obtained from fetal
liver or from umbilical cord blood has resulted in improved, long-
term engraftment of human hematopoietic cell types as well as the
ability to generate human immune responses. Combinations of the
above mutations so far analyzed for HP/HSC engraftment have
included such strains as Balb/c RAG2−/−γc−/− (referred as to
BRG), NOD RAG1−/−γc−/− (NRG), NOD–SCID-γc−/− (NSG;
Traggiai et al., 2004; Bente et al., 2005; Brehm et al., 2010; Akkina
et al., 2011). It should be noted that the methods used to prepare
human HP/HSCs and humanized BRG, NRG, and NSG mice are
relatively straightforward (Baenziger et al., 2008). When engrafted
with HP/HSCs, these immunocompromised strains bearing a γc
mutation have shown to support much higher levels of hemato-
lymphoid engraftment than all previous immunodeﬁcientmice, in
terms of the production of human immune cells (including T and
B cells, monocytes, macrophages, and DCs), of the reconstitution
of human cells into various organs, of the duration of engraftment,
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and of the ability to generate primary human adaptive immune
responses (Shultz et al., 2007). Recently, an analysis of the human-
ization of these three mouse strains has compared engraftment
of human HP/HSCs derived from umbilical cord blood following
intravenous injection into adult mice and intracardiac and intra-
hepatic injection into newborn mice (Ito et al., 2008; Brehm et al.,
2010). The latter exhibited enhanced engraftment as compared to
adult recipients.
Genetic background
More interestingly, immunodeﬁcient NOD strains supported
enhanced hematopoietic engraftment compared to the Balb/c
strain. Indeed, in BRG mice, human B cells develop and sur-
vive robustly, but human NK and T cells survive poorly. Thus,
the main sign of disturbed human T cell homeostasis is the low T
cell frequency in peripheral lymphoid organs. When these mice
were complemented either with human IL-7 or human MHC
molecules, that both control naive T cell homeostasis, they exhibit
enhanced human T cell numbers but only to a limited extent. Like-
wise, inoculation of BRG mice with human IL-15/IL-15Ra leads to
improved but still suboptimal NK cell accumulation. The different
cytokines knocked in these models have been reviewed (van Lent
et al., 2010; Willinger et al., 2011).
Interestingly, as the NOD genetic background is known for its
defective phagocyte activity, it was inferred that the activity of
macrophages and other phagocytic cells plays a role in T and NK
cell number regulation. Knowing that the phagocyte activity is
inhibited by interactions of CD47 with signal regulatory protein
alpha (SIRPα: CD172a), two different experimental approaches
have led to the demonstration that functional CD47/SIRPα inter-
actions are required for optimal human T and NK cell homeostasis
in vivo. The ﬁrst experimental approach consisted in the introduc-
tion of CD47/SIRPα interactions in BRG HIS mice by transducing
mouse CD47 into HP/HSC (Legrand et al., 2011). The second
experimental approach consisted in the generation of mice that
express SIRPα in BRG mice (Legrand et al., 2011; Strowig et al.,
2011). Both procedures resulted in an important and selective
improvement of HP/HSCs engraftment and of human T and
NK cell homeostasis. Even if a moderate increase of B cells was
observed, total plasma IgG and IgM concentrations signiﬁcantly
increased. Finally, an improved functionality of the HIS was
revealed in thesemice,which are comparable toNSGmice. Clearly,
CD47/SIRPα interaction appears as a major determinant of escape
from phagocyte-mediated cell clearance.
Whatsoever, these current humanized mouse models cannot
develop a robust adaptive immune response. Indeed these mice do
not expressHLAmolecules on thymic epithelial cells and humanT
cells lack the ability to recognize antigen in anHLA-restrictedman-
ner. To achieve that HLA restriction in vivo, an immunodeﬁcient
NSG-HLA-A2 strain was created, by backcrossing the HLA class I
transgene onto the NSG background (Strowig et al., 2009; Shultz
et al., 2010). Transplantation of puriﬁed human HP/HSCs into
NSG-HLA-A2 newborns resulted in functional CD4+ and CD8+
T cells expressing cytotoxic molecules and generating cytokines in
vivo. Furthermore, these humanized NSG-HLA-A2 mice demon-
strated functional HLA-restricted CTL in in vivo EBV or Dengue
virus infection models (Jaiswal et al., 2009; Shultz et al., 2010).
Table 1 | Infectious agents studied in humanized mice.
Pathogen Associated Mouse Reference
disease model
Viruses
HIV-1 AIDS BRG Baenziger et al. (2006)
NSG Watanabe et al. (2007a)
NOG Watanabe et al. (2007b)
NOD/SCID Brainard et al. (2009)
BLT
Rag1−/−γc−/− Akkina et al. (2011)
HTLV ATL, HAM/TSP NOD/SCID Banerjee et al. (2010b)
BRG Villaudy et al. (2011b)
NSG Fujisawa et al. (2011)
EBV Burkitt lymphoma BRG Traggiai et al. (2004)
NOG Yajima et al. (2008)
NSG Strowig et al. (2009)
NOD/SCID Islas-Ohlmayer et al. (2004)
NOD/SCID BLT Melkus et al. (2006)
KSHV Kaposi sarcoma NOD/SCID Wu et al. (2006)
Dengue Dengue BRG Kuruvilla et al. (2007)
virus NOD/SCID Bente et al. (2005)
HSV-2 Genital herpes BRG Kwant-Mitchell et al. (2009)
HCV Hepatitis C BRG Fah−/− Bissig et al. (2010)
HBV Hepatitis B BRG Fah−/− Bissig et al. (2010)
BRH uPa−/− Dandri et al. (2001)
CMV Cytomegalovirus NSG Smith et al. (2010)
infection
Bacteria
Salmonella Typhoid fever BRG Traggiai et al. (2004)
typhi
To date, the newer humanized mouse models have been exam-
ined for infection by a variety of human viruses and pathogens
including the retroviruses HTLV-1 and HIV-1, the herpes viruses
EBV, Dengue virus, hepatitis B- and C-virus, as summarized in
Table 1.
The humanized HIS mice are now used as in vivo models
in both basic and preclinical research ﬁelds. Clearly, human-
ized mice represent a potent translational model for studying
human hematopoiesis, immunity, gene therapy, infectious dis-
eases, cancer, and regenerative medicine without putting patients
at risk.
ESTABLISHING HIS MICE AS A MODEL TO STUDY HTLV-1
INFECTION AND PATHOGENESIS
Human T cell development in HIS mice
Human immune system mice are generated according to the
procedure previously described (Traggiai et al., 2004) and sum-
marized in Figure 3.
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FIGURE 3 | Generation of HIS mice from human cord blood and
Rag2−/−γc−/− newborns. (A) Representative FACS analysis for CD34,
CD3, and CD19. CD34+ cells are obtained by MACS selection from
human cord blood (upper panel). After puriﬁcation, the purity is over 90%
and the B andT cells contamination (lower than 1%, lower panel). The
percentage of CD34+ cells as well as B (CD19+) andT (CD3+) cells are
indicated on the plots. (B) Rag2−/−γc−/− newborn mice are sublethally
irradiated. (C) Schematic representation of the procedure. Puriﬁed
CD34+ cells are injected into the liver of sublethally irradiated
Rag2−/−γc−/− newborns. This results in the development of a human
adaptive immune system in the HIS mice. (D) Sequential colonization
of the different murine organs by human cells. The humanization can
be observed for several months after birth. +/−, less than 5%; +,
5–20%.
An efﬁcient intrathymic de novo development of human T cells
is a major prerequisite for humanized mice to be retained as con-
venient models for human T lymphotropic viruses, such as HIV-1
and HTLV-1. The thymus of newborns HIS (BRG) or HIS (NSG)
mice supports human αβT and γδT cell development more efﬁ-
ciently than that of adults, probably because of the involution of
the thymic rudiment in the latter (Legrand et al., 2006b). What-
soever, the establishment of cortex and medulla-like regions are
observed within the thymic lobules of the murine thymus. Thy-
mopoiesis occurs independently of the genetic background, in a
sustained manner, as indicated by the presence of the four main
thymocyte subsets. Thus, in 8 week-old mice, the proportion of
double-negative (DN) thymocytes was in the range of 1–2%,while
that of double-positive (DP) CD4+CD8+ thymocytes range from
50 to 80%. Fairly physiological ratios of mature single-positive
(SP) CD4+ and CD8+ T cells are present with broad Vβ distribu-
tion, together with Foxp3+, CD25 regulatory T cells. Furthermore
human CD16+CD56+ NK cells are also observed in the murine
thymus.
Mature T cells exit the thymus seeding the peripheral lymphoid
organs 1–2 months after inoculation of CD34+ cells. They home
to bone marrow, spleen, liver, lungs, and peripheral blood (5–
20% of human cells). Human T cells developing in HIS mice are
functional as indicated by the proliferation of these T cells after
in vitro stimulation with allogeneic human DCs (Traggiai et al.,
2004). The observation that human T cells are able to populate
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the peripheral lymphoid organs of HIS mice indicates that these
cells have undergone a positive selection, potentially through both
human and murine MHC molecules.
Beside the development of T cells, other important lineages
develop from the human progenitors in HIS mice. The major
hematopoiesis-derived cells in HIS mice are B cells undergoing a
complete differentiation and maturation process. A low frequency
of CD56+ NK cells, CD14+ monocytes, and conventional and
plasmacytoid DCs were also reported in various analyzed organs
(Traggiai et al., 2004; Chicha et al., 2005).
Overall, one of the major point achieved by HIS mice is the efﬁ-
cient intrathymic de novo development of human T cells, that can
be easily studied to answer questions linked to retroviral infection
(Baenziger et al., 2008).
HIS mice infected with HTLV-1
The ﬁrst observations of HTLV-1 infections that established
humanized mice as in vivomodels to characterize HTLV-1 tropism
and leukemogenesis associated with HTLV-1 infection have been
performed in 1996 (Feuer et al., 1996). In that study, CD34+
HP/HSCs isolated from human fetal liver cells were productively
infected by in vitro cocultivation with HTLV-1 producing cell
lines. They were then inoculated in SCID mice engrafted with
human fetal thymus and liver tissues (SCID-hu-thy/liv). These
mice develop a conjoint organ, which supports human thymo-
cyte differentiation and maturation. Viral infection of thymocytes
was detected 4–6 weeks later. Interestingly, thymocytes from two
mice with the greatest HTLV-1 proviral burdens showed increased
expression of the CD25 marker (the IL-2 receptor alpha chain)
and perturbation of distribution proﬁles of the CD4+ and CD8+
thymocyte subsets. Even if no T cell malignancy was reported,
these observations clearly implicate the human thymus as a tar-
get reservoir for HTLV-1 infection. They further suggest that the
dysregulation of thymopoiesis and lymphoproliferation are pre-
disposing events in the development of the leukemogenic process
associated with HTLV-1 infection. It was recently reported that
sublethally irradiated 4- to 6-week NOD/SCID mice inoculated
with human fetal liver-derived CD34+ cells ex vivo infected by
HTLV-1 developed CD4+ T cell lymphomas with characteristics
similar to ATL (Banerjee et al., 2010a). Interestingly, an elevated
proliferation of infected human stemCD34+CD38− was observed
in the bone marrow of these mice. Likewise NOD/SCID mice
reconstituted with CD34+ HP/HSCs transduced with a lentivirus
vector expressing the Tax protein also developed CD4+ lym-
phomas. These observations infer thatHP/HSCs provide an in vivo
viral reservoir and act as cellular targets for leukemogenesis in
humans.
As underlined above, intensive efforts in the engineering mice
strains propitious to humanization have led to the generation of
severely immunocompromised strains able to sustain prolonged
human hematopoiesis in vivo with a higher level of engraftment
upon transplantation of CD34+ HP/HSCs puriﬁed from human
cordblood (see above section). Thehigh ability of humanizedBRG
and NSG mice to support maturation and all human hematopoi-
etic lineages should therefore facilitate the evaluation of the effects
of HTLV-1 infection. Thus, it has been reported that in NSG mice
inoculated with human fetal liver-derived CD34+ cells ex vivo
infected by HTLV-1, viral infection was skewing hematopoiesis to
the T cell lineage leading to hyperproliferation of CD3+ T cells in
the bone marrow, thymus, spleen, and mesenteric lymph nodes
(Banerjee et al., 2010a).
The ex vivo infection protocol represent a deﬁnite bias as those
cells are not naturally in vivo infected. Inoculating ex vivo HTLV-1
infected CD34+ HP/HSC in immunodeﬁcient mice is confusing
the humanization process with the infection procedure, which is
quite different of the natural infection conditions.
To mimic the conditions favoring the initiation of the leuke-
mogenic process at an early stage of T cell development, it was
thereforemore suitable to infectmice thatwere previously human-
ized. According to that experimental strategy, humanized mice
established by the intrabone marrow transplantation of NSG mice
withCD133+ HSCspuriﬁed fromhumancordbloodwere infected
with HTLV-1 in vivo by γ-ray-irradiated HTLV-1-producing T
cells, 3–4 months after transplantation (Fujisawa et al., 2011).
It was reported that HTLV-1 infection increased the number of
CD25+CD4+ T cells and resulted in splenomegaly. Interestingly,
during the late period of infection, when almost all the cells
were infected T lymphocytes, the presence of highly lobulated
or ﬂower-shaped nuclei appeared in the peripheral blood.
In another study, newborn BRG mice that were intrahepati-
cally inoculated with CD34+ HP/HSC isolated from human cord
bloodwere intraperitoneally injectedwith γ-ray-irradiatedHTLV-
1-producing T cells, 6–8 weeks after transplantation, at a time
when the three main subpopulations of human thymocytes could
be detected (Villaudy et al., 2011b). In control animals, i.e., in
non-humanized BRG mice infected with HTLV-1, the proviral
sequences are not detected. Conversely, the provirus sequences
are readily integrated in the human genome in cells from periph-
eral organs of infected humanized BRG mice up to 8 months after
infection. This persistent infectionwas correlatedwith anovertime
increase of the PVL. Under these conditions, HTLV-1 is inducing
alterations of human thymopoiesis, that correlates with level of
the proviral load, with an expansion of mature CD4+/CD25+
T cells and with the development of pathological features, such
as splenomegaly and lymphoma phenotypically similar to those
found in ATL patients.
Interestingly, these pathologies are associated with a profound
deregulation of the T cell development in the infected animals
and resulted in the accumulation of infected T cells with a mature
phenotype (CD4+ or CD8+). In this in vivo model, genes involved
in the anti-apoptotic pathway are deregulated in a manner similar
to that observed in in vitro Tax-transduced human thymocytes
(Wencker et al., 2007, 2009).
HTLV-1 infects human immature thymocytes
To determine in which cells the HTLV-1 provirus is integrated,
CD3+ cells and CD3− cells were isolated from human CD45-
expressing thymocytes of infected HIS mice (Figure 4).
The CD3− thymocytes represent immature thymocytes: the
early progenitors, the immature CD4 SP population and the early
DP T cells. The CD3+ thymocytes encompass a mature popula-
tion with the late DP thymocytes along with SP CD4+ or CD8+
cells. The level of proviral load in both populations was evaluated
and was found to be about 40-fold higher in the CD3+ than that in
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FIGURE 4 | HumanT cell leukemia virus type 1 (HTLV-1) provirus is
detected in immature thymocytes and higher PVL is found in more
mature thymocytes.The cells isolated from the thymus of four animals
infected at the age of 4 weeks and sacriﬁced at 18 weeks (#594 and #595)
or 31 weeks (# 586 and #589) were sorted on their expression of CD3.
Proviral load (PVL) was measured on the DNA extracted form the two
sorted populations. Except for the mouse #594, the PVL in the CD3+
populations is higher. PVL is deﬁned as the number of copies of HTLV-1 in
100,000 human cells.
Table 2 |The humanT cell development is altered in HTLV-1 infected
HIS Rag2−/−γc−/− mice.
Immature DP SP
Percent of human thymocytes in mock-infected animals
Early 18 (3–23) 45 (30–70) 38 (25–60)
Late 10 (5–20) 45 (35–60) 38 (26–58)
Percent of human thymocytes in HTLV-1-infected animals
Low PVL 20 (2–38) 58 (40–80) 20 (10–40)
High PVL 2 (0–4) 15 (0–38) 75 (50–95)
Composite data from mock-infected mice and from HTLV-1-infected mice sac-
riﬁced early (early and low PVL, respectively) and late (late and high PVL,
respectively) after CD34+ cell transplantation. Data represent mean ± SD of per-
cent of human CD45+ thymocytes that are CD4−CD8− and CD4ISP immature
cells, DP cells, and SP cells in the thymus of mice.
the CD3− population. These observations indicate that immature
cells are indeed infected. One important consequence of that event
may explain that in the thymus of infected HIS mice, the mature T
lymphocytes represent the main subset when compared to the DP
and immature subsets. Indeed, no modiﬁcation in the distribution
proﬁles of these populations has been observed in mock-infected
HIS mice (Table 2). These observations indicate that the accumu-
lation of mature lymphocytes in the thymus of infected mice is
consecutive to their increased capacity of proliferation.
Consequently, the thymopoiesis alterations consecutive to
HTLV-1 infectionmay be caused by the expression of Tax in imma-
ture thymocytes. Indeed, that viral protein has been shown to
down-regulate the expression of the pTα gene, thus perturbing
β-selection, the early and critical checkpoint of human αβT
cell development in the thymus (Wencker et al., 2007, 2009).
Furthermore, the expression of Tax may be linked to the sustained
expression of NF-κB-dependent genes that may propel infected
thymocytes toward the mature stages of T cell development.
Using a highly sensitive high throughput sequencing system
described elsewhere (Gillet et al., 2011), the number of unique
integration sites (UIS) as well as the respective size of each
clone detected in the spleen of several animals have indicated
a polyclonal integration pattern. Interestingly, the analysis of
the clonality of different organs in one mouse indicated major
differences in the clonal distribution with a high number of UIS
in the thymus of this mouse whereas the number of clones in the
spleen and the lymph nodes was lower and some clones were quite
large in comparison to the others.
FUTURE PROSPECTS
Thanks to the successive modiﬁcations of the model systems and
genetic manipulation, humanized mice have acquired the abil-
ity to serve as preclinical models for the in vivo study of human
cells and tissues. Humanized mice could provide valuable infor-
mation about the cellular and molecular in vivo mechanisms
supporting the leukemogenic activity of HTLV-1. In addition,
they are potentially very helpful for the evaluation of therapeutic
treatments.
As suggested in this manuscript, the infected HIS mouse model
represents a promising preclinical tool to study new therapeutic
treatments. Therapies could be evaluated in collaboration with
clinicians to interfere at different times after infection. Treatment
to block the entry or the replication of the virus could be assessed
in order to serve as a post-exposure way to prevent the persistent
infection. A treatment, involving the use of IFN-α, zidovudine
(AZT), and As2O3 has been tested on several patients and has
shown promising results as a ﬁrst-line therapy for ATL patients
(Bazarbachi et al., 2010). The molecular and cellular mechanisms
involved in this treatment are not yet understood and should ben-
eﬁt from the humanized mouse model. An attempt to elucidate
the exact mechanisms was described (Villaudy et al., 2011a).
Intraperitoneal inoculation of HTLV-1-producing cells have
been successfully used to infect HIS mice with other human
viruses like HIV and represent the easiest way to administrate
infected cells into the mice. Oral inoculation is more relevant
to the route of natural HTLV-1 infection occurring through
breast-feeding, as ATL has been linked to the infection of new-
born mostly via breast-feeding by an HTLV-1 infected mother
(Hasegawa et al., 2003).
The use of molecular clones to infect the HIS mouse model
would represent a powerful tool to dissect the role of the differ-
ent viral proteins and particularly the regulatory proteins such as
Tax, HBZ, Rex, and p30 in an in vivo infection and pathogenic
processes. This model also represents a good opportunity of
understanding the leukemogenic potential of HTLV-1 in a com-
parative study with HTLV-2 and HTLV-3 which are closely related
to HTLV-1 but have different pathogenesis. HTLV-2 has not
been associated with any malignant diseases. The pathogenesis
of HTLV-3 is unknown due to the low number of known infected
people around the world. The infection of HIS mice with HTLV-2
could provide an interesting approach to determine what are the
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critical steps of leukemogenesis that are created by HTLV-1 and
not by HTLV-2 or HTLV-3.
Humanizedmice aremainly instrumental in dissecting the early
stages of the infection and the critical initial events leading to the
development of ATL-like pathologies. It should be emphasized
that the proliferation of infected clones is not under immune con-
trol, as the human adaptive immune response in this humanized
mouse model directed toward HTLV-1 has been very disappoint-
ing thus far (Villaudy andDucDodon, unpublished observations).
The use of alternative immunosuppressed mice strains, such as the
NSG-HLA-A2 mice could resolve this problem and improve this
model, providing researchers and clinicians with a valuable tool
not only to investigate the early steps of leukemogenesis, but also
to unravel what is happening during the long latent period follow-
ing HTLV-1 infection. Over the past three decades, the technology
and applications of humanized mouse model have considerably
grown providing new opportunity for human retroviral studies
and for testing the efﬁcacy of anti-retroviral therapies. The recent
development of optimized humanized mice offer great promise
in the ﬁeld of retrovirology knowledge, and reasonable hopes
for the development of therapies against this virus-associated
cancer.
CONCLUDING REMARKS
A better knowledge of viral pathogenesis is required to provide
comprehensive novel treatments (therapies and vaccines) to elimi-
nate viral infections in humans. Clearly, progress in understanding
the cellular and molecular basis of viral pathogenesis has come
fromanimalmodels. Like for allmodeling approaches that use sur-
rogates, one main limitation concerns the validity of extrapolating
data derived from speciﬁc experiments using animal models to
the general human clinical conditions. Nevertheless, it should be
emphasized that animal models have largely participated to the
study of viral pathogenesis, and as underlined in this review, they
have greatly contributed to delineate main aspects of HTLV-1
pathology. It is not surprising that these models include rab-
bits, rats, and mice, i.e., three of the main laboratory animals.
Their use to study viral pathogenesis has led to complementary
data. Indeed, the ﬁrst two of them – rabbits and rats – can be
infected with HTLV-1 and have been used to address essential
issues, such as entrance and spread in the host, and the devel-
opment of the immune response. Conversely, mice that cannot
be infected with HTLV-1 have ﬁrst been instrumental either as
immunodeﬁcient strains or as transgenic models. Later on, the
generation of humanized mice developing a HIS has generated
new hopes in the ﬁeld of human infectious diseases and rep-
resent a physiologically potent system allowing studies of direct
interactions of HTLV-1 with human hemato-lymphoid cells. Nev-
ertheless, the present survey of the literature devoted to animal
models of HTLV-1 infection and pathogenesis has underlined the
speciﬁcity as well as the complementarity of each of these models.
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